Statins Diminish Major CV Events in Diabetic Patients Without Obstructive CAD
In a recently published study in the European Heart Journal–Cardiovascular Pharmacotherapy, researchers explored the effectiveness of aspirin and statin treatment on cardiovascular (CV) and bleeding prevalence in patients with diabetes and no obstructive coronary artery disease (CAD) as
assessed by coronary angiography. Read more.

Semaglutide Injection Approved for Weight Management in Patients With Hypertension, Dyslipidemia, or Diabetes
Last month, the FDA approved the first once-weekly glucagon-like peptide-1 receptor agonist, semaglutide injection, for weight management. The drug, which will be marketed as Wegovy, is indicated as an adjunct to diet and exercise for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Read more.

Cardiometabolic Biomarkers Not Improved With High-Dose Vitamin D
Various studies have proposed a connection between vitamin D and cardiovascular and metabolic disease, but this link has not been validated in randomized, controlled clinical trials. In a recent publication in the Journal of the American Heart Association, researchers attempted to ascertain whether supplementation with vitamin D can lessen cardiometabolic biomarkers. Read more.